nivolumab,ipilimumab,cabozantinib,sunitinib
bms,pfizer
['nivolumab', 'cabozantinib', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'check,mate,9er', 'biomarker', 'nivo', 'marker ']
at asco #gu23 's presents biomarker data from checkmate-9er trial and says more work is needed to identify potential biomarkers predictive of the doublet nivolumab+cabozantinib efficacy. cc: 
Your official source for @DanaFarber Cancer Institute news | Research, science, and innovation | Media requests: media@dfci.harvard.edu or 617-632-4090